NCT03228017View on ClinicalTrials.gov

Subclinical Cardiovascular Disease in Psoriatic Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

April 1, 2019

Study Completion Date

April 1, 2019

Conditions
Cardiovascular DiseasesMyocardial InfarctionAtherosclerotic Cardiovascular DiseaseThrombotic Vascular Disease
Interventions
DRUG

Aspirin and/or Atorvastatin

This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.

Trial Locations (1)

10016

New York University School of Medicine, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT03228017 - Subclinical Cardiovascular Disease in Psoriatic Disease | Biotech Hunter | Biotech Hunter